KemPharm, Inc. (KMPH)
| Market Cap | 342.40M |
| Revenue (ttm) | 28.39M |
| Net Income (ttm) | -66.30M |
| Shares Out | 29.17M |
| EPS (ttm) | -4.63 |
| PE Ratio | n/a |
| Forward PE | 28.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,064,283 |
| Open | 9.67 |
| Previous Close | 9.74 |
| Day's Range | 9.44 - 10.80 |
| 52-Week Range | 5.08 - 18.15 |
| Beta | 3.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Oct 28, 2021 |
About KMPH
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CN...
Financial Performance
In 2020, KemPharm's revenue was $13.29 million, an increase of 3.50% compared to the previous year's $12.84 million. Losses were -$12.76 million, -47.97% less than in 2019.
Financial StatementsNews
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at M...
CELEBRATION, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
Trading to commence effective with the open of business on October 19, 2021
KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...
KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...
KemPharm Appoints Tamara A. Seymour to Board of Directors
CELEBRATION, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today t...
How to Pick the Best Small Cap Biotech Stocks to Buy
Investing in biotech stocks isn't for the faint of heart, but these can be some of the most lucrative equities on the market. The post How to Pick the Best Small Cap Biotech Stocks to Buy appeared first...
KemPharm to Report Second Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate c...
CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced t...
Why KemPharm Stock Sank Today
Investors reacted negatively to the company's warrant exchange.
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced i...
KemPharm Issues Letter to Shareholders
CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
Why This News Could Help KemPharm Stock Break Out: A Technical Analysis
KemPharm Inc. (NASDAQ:KMPH) shares moved higher Thursday after it was announced the company is being added to the Russell 3000 and Russell 2000 indexes based on the index provider's annual reconstitutio...
KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today i...
KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences
CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of...
SDX is KemPharm's proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™
KemPharm Reports First Quarter 2021 Financial Results
Corporate and Regulatory Highlights
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
KP879, KemPharm's Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA
KemPharm to Report First Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET
KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with A...
Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX
KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M
KemPharm Inc (NASDAQ: KMPH) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to d...
KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZS...
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales
KemPharm Stock Is Too Good to Be True After Its Recent Run-up
KemPharm has a new ADHD drug, but after a recent short-squeeze KMPH stock is likely to fall without further financing. The post KemPharm Stock Is Too Good to Be True After Its Recent Run-up appeared fir...
Are Options Traders Betting on a Big Move in KemPharm (KMPH) Stock?
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Squeeze
KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME). The post KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Sque...
KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
Corporate and Regulatory Highlights: